Grifols, S.A. General and Administrative Expenses 2011-2026 | GRFS

General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.

What these expenses include

Salaries of administrative staff (executives, HR, accountants, legal personnel)
Office rent and utilities
Office equipment and IT infrastructure
Professional services (auditors, lawyers, consultants)
Insurance
General administrative travel and representation expenses

What the metric indicates

Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure
Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit
Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry
Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines

Annual General and Administrative Expenses Grifols, S.A.

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	1.06 B	-	-	-	-	-	-	-	-	-	-

All numbers in EUR currency

Indicator range from annual reports

Maximum	Minimum	Average
1.06 B	1.06 B	1.06 B

General and Administrative Expenses of other stocks in the Biotechnology industry

Issuer	General and Administrative Expenses	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	78.3 M	-	2.43 %	$ 254 M	Germany
BioNTech SE BNTX	286 M	$ 95.5	-3.88 %	$ 27.2 B	Germany
AgeX Therapeutics AGE	11 M	-	-10.17 %	$ 12.2 K	USA
I-Mab IMAB	900 M	-	-	$ 866 M	China
Midatech Pharma plc MTP	4.95 M	-	-18.52 %	$ 27.3 M	Britain
Alexion Pharmaceuticals, Inc. ALXN	1.4 B	-	-	$ 40.3 B	USA
Biophytis SA BPTS	7.15 M	-	-13.47 %	$ 169 M	France
Genfit SA GNFT	16.2 M	-	2.54 %	$ 160 B	France
EyeGate Pharmaceuticals, Inc. EYEG	4.66 M	-	-1.52 %	$ 24.7 M	USA
Athira Pharma ATHA	16.7 M	-	-	$ 269 M	USA
Институт стволовых клеток человека ISKJ	25.8 M	-	-	-	Russia
Checkmate Pharmaceuticals CMPI	15.7 M	-	-	$ 231 M	USA
ACADIA Pharmaceuticals ACAD	488 M	$ 22.35	0.72 %	$ 3.7 B	USA
Galapagos NV GLPG	141 M	$ 28.39	-0.13 %	$ 2.69 B	Belgium
Advaxis ADXS	12.2 M	-	-9.65 %	$ 45.9 M	USA
Can-Fite BioPharma Ltd. CANF	3.66 M	$ 3.5	5.42 %	$ 5.76 M	Israel
Aeterna Zentaris AEZS	5.92 M	-	5.93 %	$ 314 M	Canada
Aeglea BioTherapeutics AGLE	47.9 M	-	-	$ 1.01 B	USA
CureVac N.V. CVAC	100 M	-	-	$ 867 M	Germany
Applied Genetic Technologies Corporation AGTC	17 M	-	-	$ 26.5 M	USA
AIkido Pharma AIKI	23.8 M	-	1.93 %	$ 17.4 M	USA
InflaRx N.V. IFRX	12 M	$ 1.97	-7.51 %	$ 152 M	Germany
Akero Therapeutics AKRO	37.9 M	-	-	$ 3.67 B	USA
Aptose Biosciences APTO	13.4 M	-	-45.71 %	$ 1.2 M	Canada
Aptinyx APTX	19.8 M	-	-39.0 %	$ 4.57 M	USA
Akouos AKUS	22.2 M	-	0.23 %	$ 488 M	USA
Albireo Pharma ALBO	69.6 M	-	-0.23 %	$ 916 M	USA
Allakos ALLK	45.1 M	-	-	$ 28.6 M	USA
AlloVir ALVR	11 M	-	4.14 %	$ 49.1 M	USA
Arcutis Biotherapeutics ARQT	275 M	$ 23.42	-0.3 %	$ 2.98 B	USA
Allena Pharmaceuticals ALNA	12.7 M	-	3.16 %	$ 1.9 M	USA
Ampio Pharmaceuticals AMPE	7.08 M	-	-11.43 %	$ 502 K	USA
Applied Molecular Transport AMTI	37.4 M	-	-	$ 10.1 M	USA
Alpine Immune Sciences ALPN	18 M	-	-	$ 2.17 B	USA
Aileron Therapeutics ALRN	10.9 M	-	10.36 %	$ 9.8 M	USA
Applied Therapeutics APLT	20.6 M	-	-	$ 8.42 M	USA
Aravive ARAV	13 M	-	-13.39 %	$ 1.45 M	USA
Aridis Pharmaceuticals ARDS	7.16 M	-	17.91 %	$ 11.1 M	USA
Innate Pharma S.A. IPHA	25.5 M	$ 1.4	-2.1 %	$ 235 M	France
CRISPR Therapeutics AG CRSP	73.5 M	$ 52.38	-2.24 %	$ 4.71 B	Schweiz
Avenue Therapeutics ATXI	3.65 M	-	-52.27 %	$ 4.45 M	USA
Autolus Therapeutics plc AUTL	132 M	$ 1.64	4.46 %	$ 436 M	Britain
Inventiva S.A. IVA	11.2 M	$ 5.42	2.85 %	$ 138 M	France
AVROBIO AVRO	24 M	-	1083.1 %	$ 745 M	USA
Ayala Pharmaceuticals AYLA	1.53 M	-	-	$ 7.46 M	Israel
Завод ДИОД DIOD	19.7 M	-	-	-	Russia
Фармсинтез LIFE	24.1 M	-	-	-	Russia
AstraZeneca PLC AZN	15.2 B	-	-	$ 96.9 B	Britain
Atreca BCEL	31.5 M	-	-11.76 %	$ 5.79 M	USA